NYSE:PFE - Pfizer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$42.14 -0.06 (-0.14 %)
(As of 02/22/2019 07:15 AM ET)
Previous Close$42.20
Today's Range$41.86 - $42.32
52-Week Range$34.32 - $46.47
Volume17.62 million shs
Average Volume25.96 million shs
Market Capitalization$250.85 billion
P/E Ratio14.05
Dividend Yield3.41%
Beta0.77
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; Zenith Epigenetics Ltd., and Kineta Immuno-Oncology, LLC, as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.65 billion
Cash Flow$3.8344 per share
Book Value$12.02 per share

Profitability

Net Income$11.15 billion

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000
Market Cap$250.85 billion
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Friday, December 14th. Shareholders of record on Friday, February 1st will be given a dividend of $0.36 per share on Friday, March 1st. This represents a $1.44 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date is Thursday, January 31st. This is a boost from Pfizer's previous quarterly dividend of $0.34. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its board has authorized a stock repurchase program on Friday, December 14th 2018, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 3.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, January, 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.01. The biopharmaceutical company had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. Pfizer had a return on equity of 25.38% and a net margin of 20.79%. Pfizer's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter last year, the company posted $0.62 earnings per share. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share guidance of $2.82-2.92 for the period, compared to the Thomson Reuters consensus estimate of $3.04. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $54.31 billion.Pfizer also updated its FY 2019 guidance to $2.82-2.92 EPS.

What price target have analysts set for PFE?

21 analysts have issued 1-year target prices for Pfizer's shares. Their forecasts range from $37.00 to $55.00. On average, they anticipate Pfizer's share price to reach $45.1111 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 1 sell rating, 13 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)
  • 2. According to Zacks Investment Research, "Pfizer is working on strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. However, many key drugs in Pfizer’s portfolio are facing declining sales due to generic competition. Pfizer revenues are also being affected by lower sales in the EH segment, pricing pressure and rising competition. EH revenues are being hurt by generic competition for some key products, lower revenues from sterile injectables portfolio due to continued legacy Hospira product shortages in the United States and lower sales of legacy Established Products in developed markets. Additionally, Pfizer’s shares have underperformed the industry this year so far.  Estimates have gone down slightly ahead of Q4 earnings release. Pfizer has a positive record of earnings surprises in recent quarters." (1/25/2019)

Has Pfizer been receiving favorable news coverage?

Media headlines about PFE stock have been trending very negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfizer earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.

Are investors shorting Pfizer?

Pfizer saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 42,750,118 shares, a decline of 8.8% from the January 15th total of 46,873,778 shares. Based on an average daily volume of 33,192,644 shares, the short-interest ratio is currently 1.3 days. Currently, 0.7% of the shares of the company are sold short. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), General Electric (GE), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), Bank of America (BAC), Exxon Mobil (XOM), Merck & Co., Inc. (MRK) and JPMorgan Chase & Co. (JPM).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply, Bus. Operations and Manufacturing Operations of Pfizer Global Supply (Age 61)
  • Dr. Mikael Dolsten, Chief Medical Officer and Global Pres of Worldwide R&D and Medical (Age 60)
  • Mr. John D. Young, Chief Bus. Officer (Age 54)
  • Ms. Loretta V. Cangialosi, Sr. VP, Controller & Principal Accounting Officer

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.78%), Oregon Public Employees Retirement Fund (1.68%), Northern Trust Corp (1.31%), Geode Capital Management LLC (1.26%), Bank of New York Mellon Corp (1.10%) and Massachusetts Financial Services Co. MA (0.95%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Bank of New York Mellon Corp, Nordea Investment Management AB, Barrow Hanley Mewhinney & Strauss LLC, Massachusetts Financial Services Co. MA, American International Group Inc., Macquarie Group Ltd. and Sound Shore Management Inc. CT. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, California Public Employees Retirement System, Bessemer Group Inc., Legal & General Group Plc and KAMES CAPITAL plc. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $42.14.

How big of a company is Pfizer?

Pfizer has a market capitalization of $250.85 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,247 (Vote Outperform)
Underperform Votes:  737 (Vote Underperform)
Total Votes:  1,984
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel